Smart Combination Respiratory Medicines for Optimal & Cost Effective Patient Benefit
Lead Participant:
PROSONIX LIMITED
Abstract
The Business-led APPS2B Project aims to identify, demonstrate, and quantify for the first time the mechanism for, and potential significant clinical benefits of hihghly innovative orally inhaled combination respiratory therapies, that have been optimally designed, engineered and manufactured for intent using Prosonix Multi-Component Particle (MCP) Technology.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| PROSONIX LIMITED | £2,121,958 | £ 904,379 |
Participant |
||
| IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE | £126,627 | £ 126,627 |
| BATH SPA UNIVERSITY | £92,546 | £ 92,546 |
| KING'S COLLEGE LONDON | £94,085 | £ 94,085 |
People |
ORCID iD |
| Andrew Bush (Project Manager) |